SLC5A2 and chronic kidney disease: Higher median household income was associated with a higher rate of SGLT2 inhibitor use across all subgroups (HFrEF: aOR, 1.21 [95% CI, 1.08-1.34] for income of $50 000-$99 999; aOR, 1.26 [95% CI, 1.11-1.44] for income ≥$100 000 vs <$50 000; ASCVD: aOR, 1.05 [95% CI, 1.02-1.08] for income of $50 000-$99 999; aOR, 1.08 [95% CI, 1.05-1.12] for income ≥$100 000 vs <$50 000; CKD: aOR, 1.15 [95% CI, 1.07-1.24] for income ≥$100 000 vs <$50 000).